Cyclo(Arg-Gly-Asp-D-Phe-Cys)
目录号 : GA21303
Cyclo(Arg-Gly-Asp-D-Phe-Cys)，通常缩写为cRGDfC，是一种环状RGD肽，对整合素αvβ3具有高亲和力和选择性。
Cas No.:862772-11-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cyclo(Arg-Gly-Asp-D-Phe-Cys), commonly abbreviated as cRGDfC, is a cyclic RGD peptide that shows high affinity and selectivity for the integrin αvβ3 [1]. Treatment of murine embryonic stem cells (mESCs) with Cyclo(Arg-Gly-Asp-D-Phe-Cys) peptide can induce some cells to express early ectoderm lineage markers [2]. Cyclo(Arg-Gly-Asp-D-Phe-Cys) is mainly used to modify liposomes and other delivery systems to achieve targeted drug delivery to tumor tissues [3-4].
In murine embryonic stem cells, Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5mM; 24 h) down-regulated the transcription factors Oct 4, Sox 2, and Nanog [2].
References:
[1]. Nallamothu R, Wood GC, Pattillo CB, et al. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation. Aaps Pharmscitech. 2006 Jun; 7: E7-16.
[2]. Hazenbiller O, Duncan NA, Krawetz RJ. Reduction of pluripotent gene expression in murine embryonic stem cells exposed to mechanical loading or Cyclo RGD peptide. BMC Cell Biology. 2017 Dec; 18: 1-5.
[3]. Chen Z, Deng J, Zhao Y, et al. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. International journal of nanomedicine. 2012 Jul 18: 3803-3811.
[4]. Xia Y, Chen Y, Hua L, et al. Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy. International Journal of Nanomedicine. 2018 Oct 30: 6929-6939.
Cyclo(Arg-Gly-Asp-D-Phe-Cys)，通常缩写为cRGDfC，是一种环状RGD肽，对整合素αvβ3具有高亲和力和选择性 [1]。用Cyclo(Arg-Gly-Asp-D-Phe-Cys)肽处理小鼠胚胎干细胞（mESC）可诱导部分细胞表达早期外胚层谱系标志物 [2]。Cyclo(Arg-Gly-Asp-D-Phe-Cys)主要用于修饰脂质体和其他递送系统，以实现药物向肿瘤组织的靶向递送 [3-4]。
在小鼠胚胎干细胞中，Cyclo(Arg-Gly-Asp-D-Phe-Cys)（0.5mM；24h）下调了转录因子Oct 4、Sox 2和Nanog [2]。
| Cell experiment [1]: | |
Cell lines | Murine embryonic stem cells (mESCs) |
Preparation Method | Murine embryonic stem cells (mESCs) were embedded in a type I collagen matrix. Briefly, mESCs at passage 8 to 10 were trypsinized and re-suspended in β-glycerol phosphate medium (βGP). βGP medium consisted of high glucose 5 × DMEM powder medium supplemented with 10mM βGP and with FBS, NEAA, penicillin-stereptomycin solution, and βME equal to the standard cell culture procedure. To prepare one collagen construct, 1,000,000 cells were re-suspended in 200μL βGP medium and mixed with 800μL of bovine collagen type I solution (3mg/mL) and of 20μL sodium hydroxide. For the integrin studies, Cyclo(Arg-Gly-Asp-D-Phe-Cys) (cRGDfC) peptide was dissolved in 3% citric acid and this was supplemented to mESC-Col I solution to achieve a final concentration of 0.5mM cRGDfC. Finally, mESC-Col I solution, in the presence and absence of cRGDfC peptide, was pipetted into a 12 well plate and allowed to polymerize in a humidified incubator with 5% CO2 at 37℃. |
Reaction Conditions | 0.5mM; 24h |
Applications | Cyclo(Arg-Gly-Asp-D-Phe-Cys) down-regulated the transcription factors Oct 4, Sox 2, and Nanog in mESCs. |
References: | |
| Cas No. | 862772-11-0 | SDF | |
| Canonical SMILES | N=C(NCCC[C@@]1([H])/C(O)=N/C/C(O)=N/[C@@](/C(O)=N/[C@](/C(O)=N/[C@@](/C(O)=N/1)([H])CS)([H])CC2=CC=CC=C2)([H])CC(O)=O)N | ||
| 分子式 | C24H34N8O7S | 分子量 | 578.65 |
| 溶解度 | DMSO: 50 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7282 mL | 8.6408 mL | 17.2816 mL |
| 5 mM | 0.3456 mL | 1.7282 mL | 3.4563 mL |
| 10 mM | 0.1728 mL | 0.8641 mL | 1.7282 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet